- Home
- RPTX
as 12-20-2024 4:00pm EST
Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.
| Founded: | 2016 | Country: | Canada |
| Employees: | N/A | City: | SAINT-LAURENT |
| Market Cap: | 141.1M | IPO Year: | 2020 |
| Target Price: | $7.00 | AVG Volume (30 days): | 709.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.99 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.23 - $8.49 | Next Earning Date: | 11-07-2024 |
| Revenue: | $66,524,000 | Revenue Growth: | 18.19% |
| Revenue Growth (this year): | 13.22% | Revenue Growth (next year): | -88.17% |
Latest Repare Therapeutics Inc. News
RPTX Breaking Stock News: Dive into RPTX Ticker-Specific Updates for Smart Investing
MT Newswires
9 days ago
Top Midday Decliners
Benzinga
9 days ago
Why Is Repare Therapeutics Stock Trading Lower On Friday?
GuruFocus.com
9 days ago
Repare Therapeutics Shares Drop 38% Following Phase 1 Trial Results
Clinical Trials Arena
9 days ago
Repare Therapeutics eyes Phase III cancer study after Mythic trial success
MT Newswires
9 days ago
Top Premarket Decliners
MT Newswires
10 days ago
Repare Therapeutics Shares Fall as Phase 1 Trial Results for Cancer Drugs Disappoint Investors
Business Wire
10 days ago
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial
Business Wire
12 days ago
Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial
Compare RPTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RPTX Repare Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.